FLUMIST (Influenza, Vaccine Live, Intranasal), the nationâs only nasal spray flu vaccine, now available for home delivery
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMISTÂź (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.1 Initially approved by the Food and Drug Administration (FDA) in 2003, this recent approval extends a safe and effective vaccin
Related Questions
Will the home delivery model drive higher market penetration among the 18â49 adult segment and increase overall flu vaccine market share?
What regulatory hurdles remain for expanding the selfâadministration indication beyond the current age groups?
What reimbursement and insurance coverage challenges might arise for a selfâadministered nasal spray vaccine?
Are there any supplyâchain or manufacturing constraints that could limit the rollout or affect margins?
How might this product launch influence analyst sentiment and the AZN stock price in the short term?
What is the estimated adoption rate for homeâdelivery flu vaccines and how will it impact AstraZeneca's longâterm growth strategy?
Will the launch of FluMist Home open opportunities for similar atâhome delivery models for other vaccines in AstraZenecaâs pipeline?
How will the introduction of FluMist Home affect AstraZeneca's quarterly revenue and earnings forecasts?
What pricing strategy will AstraZeneca employ for the atâhome delivery service and how will it compare to existing flu vaccine pricing?
How does FluMist Home compare to competing flu vaccines (e.g., injectable Fluzone, highâdose vaccines, and other nasal spray candidates) in terms of efficacy, safety, and convenience?